725 related articles for article (PubMed ID: 28520851)
41. Assessing Knowledge, Attitudes, and Preventive Practices Related to Kala-A: A Study of Rural Madhepura, Bihar, India.
Govil D; Sahoo H; Pedgaonkar SP; Chandra Das K; Lhungdim H
Am J Trop Med Hyg; 2018 Mar; 98(3):857-863. PubMed ID: 29280426
[TBL] [Abstract][Full Text] [Related]
42. Post-kala-azar dermal leishmaniasis--an overview.
Ganguly S; Das NK; Barbhuiya JN; Chatterjee M
Int J Dermatol; 2010 Aug; 49(8):921-31. PubMed ID: 21128917
[TBL] [Abstract][Full Text] [Related]
43. An unusual paediatric case of post-kala-azar dermal leishmaniasis: a hidden parasite under the veil of white.
Arora A; Mohta A
Clin Microbiol Infect; 2023 Jun; 29(6):803-804. PubMed ID: 36918142
[No Abstract] [Full Text] [Related]
44. Genetic markers for antimony resistant clinical isolates differentiation from Indian Kala-azar.
Khanra S; Sarraf NR; Das S; Das AK; Roy S; Manna M
Acta Trop; 2016 Dec; 164():177-184. PubMed ID: 27629023
[TBL] [Abstract][Full Text] [Related]
45. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A; Singh VK; Tiwari R; Madhukar P; Rajneesh ; Kumar S; Gautam V; Engwerda C; Sundar S; Kumar R
Front Immunol; 2023; 14():1236952. PubMed ID: 37638047
[TBL] [Abstract][Full Text] [Related]
46. Epidemiology of Post-Kala-azar Dermal Leishmaniasis.
Ghosh P; Roy P; Chaudhuri SJ; Das NK
Indian J Dermatol; 2021; 66(1):12-23. PubMed ID: 33911289
[TBL] [Abstract][Full Text] [Related]
47. The molecular characterization of clinical isolates from Indian Kala-azar patients by MLEE and RAPD-PCR.
Manna M; Majumder HK; Sundar S; Bhaduri AN
Med Sci Monit; 2005 Jul; 11(7):BR220-7. PubMed ID: 15990683
[TBL] [Abstract][Full Text] [Related]
48. Decreased Frequency and Secretion of CD26 Promotes Disease Progression in Indian Post Kala-azar Dermal Leishmaniasis.
Mukherjee S; Mukhopadhyay D; Ghosh S; Barbhuiya JN; Das NK; Chatterjee M
J Clin Immunol; 2016 Jan; 36(1):85-94. PubMed ID: 26644312
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of anti-gal enzyme-linked immunosorbent assay for the diagnosis of Indian post-kala-azar dermal leishmaniasis.
Datta S; Ghosh M; Sarkar S; Saha B; Mukhopadhyay S
Indian J Dermatol Venereol Leprol; 2019; 85(6):578-589. PubMed ID: 31397399
[TBL] [Abstract][Full Text] [Related]
50. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S59-76. PubMed ID: 11370251
[TBL] [Abstract][Full Text] [Related]
51. Post kala-azar dermal leishmaniasis: A threat to elimination program.
Gedda MR; Singh B; Kumar D; Singh AK; Madhukar P; Upadhyay S; Singh OP; Sundar S
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008221. PubMed ID: 32614818
[TBL] [Abstract][Full Text] [Related]
52. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 1993; 87(4):425-7. PubMed ID: 8249072
[TBL] [Abstract][Full Text] [Related]
53. Kala-azar: an endemic focus in Bombay.
Bhende YM; Purandare NM; Banker DD; Figueredo N; Desai SD
Indian Physician; 1949 Oct; 8(10):296-304. PubMed ID: 18268800
[TBL] [Abstract][Full Text] [Related]
54. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?
Addy M; Nandy A
Bull World Health Organ; 1992; 70(3):341-6. PubMed ID: 1638662
[TBL] [Abstract][Full Text] [Related]
55. Xenodiagnosis on dogs with visceral leishmaniasis: Canine and sand fly aspects related to the parasite transmission.
Magalhães-Junior JT; Mota TF; Porfirio-Passos G; Larangeira DF; Franke CR; Barrouin-Melo SM
Vet Parasitol; 2016 Jun; 223():120-6. PubMed ID: 27198788
[TBL] [Abstract][Full Text] [Related]
56. PCR diagnosis of visceral leishmaniasis in an endemic region, Mymensingh district, Bangladesh.
Alam MZ; Shamsuzzaman AK; Kuhls K; Schönian G
Trop Med Int Health; 2009 May; 14(5):499-503. PubMed ID: 19222820
[TBL] [Abstract][Full Text] [Related]
57. Post-kala-azar dermal leishmaniasis: recent developments.
Singh S; Sharma U; Mishra J
Int J Dermatol; 2011 Sep; 50(9):1099-108. PubMed ID: 22126871
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological and Immunological Changes in Indian Post Kala-Azar Dermal Leishmaniasis (PKDL) Cases in relation to Treatment: A Retrospective Study.
Verma N; Bimal S; Das VN; Pandey K; Singh D; Lal CS; Singh AK; Sinha PK; Das P
Biomed Res Int; 2015; 2015():745062. PubMed ID: 26090441
[TBL] [Abstract][Full Text] [Related]
59. Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods.
Salotra P; Sreenivas G; Beena KR; Mukherjee A; Ramesh V
J Clin Pathol; 2003 Nov; 56(11):840-3. PubMed ID: 14600129
[TBL] [Abstract][Full Text] [Related]
60. Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
Moulik S; Sengupta R; Ghosh MK; Das NK; Saha B; Chatterjee M
Indian J Dermatol Venereol Leprol; 2022; 88(2):201-206. PubMed ID: 33969651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
